Pancuronium Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Pancuronium
Therapeutic Class: Neuromuscular Blocking Agent
Subclass: Non-depolarising Aminosteroid Muscle Relaxant
Specialty: Anaesthesiology
Schedule (India): Schedule H
Route(s): Intravenous (IV)
Formulations Available in India:
- Pancuronium bromide injection: 2 mg/mL in 2 mL ampoule (4 mg)
- Pancuronium bromide injection: 2 mg/mL in 5 mL ampoule (10 mg)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶️ Skeletal Muscle Relaxation during General Anaesthesia (including endotracheal intubation)
| Parameter | Details |
|
Starting dose
|
0.04–0.1 mg/kg IV bolus over 1–2 minutes |
|
Titration
|
Based on neuromuscular monitoring (train-of-four); adjust according to surgical requirement |
|
Usual maintenance dose
|
0.01–0.02 mg/kg IV bolus every 20–40 minutes |
|
Maximum dose
|
No fixed maximum; titrate to clinical response; cumulative dosing discouraged in prolonged procedures |
|
Onset
|
2–3 minutes; peak effect at 4–6 minutes |
|
Duration of action
|
60–90 minutes (longer than most other non-depolarising agents) |
Clinical Notes:
- Long duration of action; not suitable for short procedures
- Vagolytic effect causes tachycardia and mild hypertension
- Predominantly renally excreted; prolonged effect in renal impairment
- Use peripheral nerve stimulator to guide dosing
▶️ Facilitation of Mechanical Ventilation in ICU
| Parameter | Details |
|
Starting dose
|
0.06–0.1 mg/kg IV loading bolus |
|
Titration
|
Based on train-of-four monitoring; target 1–2 twitches |
|
Usual maintenance dose
|
0.01–0.05 mg/kg/hour continuous IV infusion |
|
Maximum dose
|
Titrate to effect; use lowest effective dose |
|
Duration
|
Shortest effective duration; avoid use beyond 48–72 hours if possible |
Clinical Notes:
- Not preferred for prolonged ICU use due to accumulation and prolonged recovery
- Concurrent adequate sedation and analgesia mandatory
- Consider atracurium or cisatracurium as alternatives in ICU setting
- High risk of ICU-acquired weakness with prolonged use
Secondary Indications — Adults (Off-label, if any)
Not applicable — No established off-label indications documented in Indian practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
▶️ Muscle Relaxation for Intubation and Surgical Anaesthesia
| Age Group | Starting Dose | Maintenance Dose | Clinical Notes |
|
Neonates (<1 month)
|
0.04–0.06 mg/kg IV bolus | 0.01–0.02 mg/kg IV every 40–60 min | Prolonged duration; immature renal function; specialist supervision mandatory |
|
Infants (1–12 months)
|
0.06–0.08 mg/kg IV bolus | 0.01–0.02 mg/kg IV every 30–40 min | Duration may be prolonged; careful monitoring required |
|
Children (≥1 year)
|
0.06–0.1 mg/kg IV bolus | 0.01–0.02 mg/kg IV every 20–40 min | Standard paediatric range; neuromuscular monitoring recommended |
Safety Monitoring:
- Mandatory neuromuscular monitoring (train-of-four or peripheral nerve stimulator)
- Heart rate monitoring (vagolytic effect may cause tachycardia)
- Temperature monitoring (hypothermia prolongs action)
- Continuous SpO₂ and capnography monitoring
Minimum Age: Use in neonates only under paediatric anaesthesiologist supervision due to risk of accumulation and prolonged effect from immature renal function.
Secondary Indications — Paediatrics (Off-label, if any)
Not applicable — No established off-label indications in paediatric practice.
RENAL ADJUSTMENT
| Renal Function | Recommendation |
|
Mild impairment (eGFR 60–89)
|
Use standard dose; monitor duration of effect closely |
|
Moderate impairment (eGFR 30–59)
|
Reduce dose by 25–50%; prolong dosing interval; monitor TOF closely |
|
Severe impairment (eGFR <30)
|
Reduce dose by 50% or more; significantly prolonged duration expected; avoid repeated dosing if possible |
|
Haemodialysis
|
Not effectively dialysed; use with extreme caution; prefer atracurium or cisatracurium |
Rationale: Pancuronium is approximately 40–60% renally excreted as unchanged drug. Accumulation occurs with impaired renal function leading to significantly prolonged neuromuscular blockade.
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
|
Mild impairment
|
Use standard initial dose; monitor duration of effect |
|
Moderate impairment
|
Use with caution; elimination may be delayed; reduce dose if repeated administration required |
|
Severe impairment
|
Use cautiously; prefer agents with organ-independent elimination (atracurium, cisatracurium) |
CONTRAINDICATIONS
- Known hypersensitivity to pancuronium bromide or other aminosteroid neuromuscular blocking agents
- History of anaphylaxis to any neuromuscular blocking agent
- Inability to provide adequate mechanical ventilation support
CAUTIONS
- Neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome) — extreme sensitivity; use significantly reduced doses if unavoidable
- Renal impairment — prolonged duration and accumulation; prefer alternative agents
- Hepatic impairment — may delay elimination
- Electrolyte abnormalities (hypokalaemia, hypocalcaemia, hypermagnesaemia) — potentiate blockade
- Burns (>1–2 weeks old) — resistance may develop; higher doses often required
- Elderly patients — increased sensitivity and prolonged effect due to reduced renal clearance
- Cardiovascular disease — vagolytic effect causes tachycardia and may increase myocardial oxygen demand
- Prolonged ICU use — high risk of ICU-acquired weakness/myopathy
- Hypothermia — prolongs action
- Ensure reversal agents (neostigmine + glycopyrrolate) are available
PREGNANCY
| Parameter | Details |
|
Risk category
|
No formal Indian category; limited human data but not known to be teratogenic |
|
Use in pregnancy
|
May be used when general anaesthesia required for surgery; minimal placental transfer |
|
Preferred alternatives
|
Atracurium or cisatracurium may be preferred; succinylcholine for rapid sequence induction |
|
Monitoring
|
Monitor maternal cardiovascular status (tachycardia); assess neonatal muscle tone and respiratory function at delivery |
LACTATION
| Parameter | Details |
|
Compatibility
|
Compatible with breastfeeding |
|
Drug levels in milk
|
Negligible; large molecular weight and quaternary ammonium structure limit transfer |
|
Preferred alternatives
|
None required for single procedural use |
|
Infant monitoring
|
Not necessary for short procedural use |
|
Resumption
|
May resume breastfeeding once mother is fully conscious, alert, and has recovered neuromuscular function |
ELDERLY
- Recommended starting dose: Lower end of range (0.04–0.06 mg/kg); reduce by 25–50%
- Titration: Slower; allow longer intervals between supplemental doses
- Additional risks: Prolonged duration of action due to reduced renal clearance; increased sensitivity; cardiovascular effects (tachycardia, hypertension) may be problematic
- Monitoring: Mandatory neuromuscular monitoring; ensure complete recovery (TOF ratio ≥0.9) before extubation
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Aminoglycosides (gentamicin, amikacin, tobramycin)
|
Potentiation of neuromuscular blockade; prolonged paralysis | Avoid if possible; reduce pancuronium dose; monitor closely |
|
Magnesium sulphate
|
Significant enhancement of blockade | Reduce dose substantially; critical in pre-eclampsia/eclampsia |
|
Inhalational anaesthetics (isoflurane, sevoflurane, enflurane)
|
Potentiate neuromuscular blockade | Reduce pancuronium dose by 20–40% |
|
Polymyxins (colistin)
|
Potentiate neuromuscular blockade | Monitor closely; avoid if possible |
|
Lithium
|
May prolong neuromuscular blockade significantly | Careful titration; monitor closely |
|
Succinylcholine
|
Additive or prolonged blockade when used sequentially | Allow recovery from succinylcholine before pancuronium; reduce initial dose |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Phenytoin, Carbamazepine (chronic use)
|
Resistance to non-depolarising blockers; reduced efficacy | May require higher doses; titrate to effect |
|
Corticosteroids (chronic/prolonged use)
|
Increased risk of ICU-acquired weakness/myopathy with prolonged concurrent use | Limit duration of paralysis; monitor for weakness |
|
Loop diuretics, Thiazides
|
Electrolyte shifts (hypokalaemia) may potentiate blockade | Correct electrolytes before use; monitor |
|
Calcium channel blockers
|
May enhance duration of blockade | Monitor neuromuscular function |
|
Quinidine, Procainamide
|
Potentiate neuromuscular blockade | Monitor closely |
|
Clindamycin
|
Potentiate blockade | Monitor; may require dose reduction |
COMMON ADVERSE EFFECTS
- Tachycardia (vagolytic effect)
- Mild hypertension
- Prolonged neuromuscular blockade (dose-dependent)
- Injection site reactions
- Salivation (infrequent)
SERIOUS ADVERSE EFFECTS
- Anaphylaxis/Anaphylactoid reactions — rare but potentially fatal; immediate discontinuation and resuscitation required
- Prolonged paralysis — requiring extended mechanical ventilation; more common than with shorter-acting agents
- Respiratory arrest — if ventilatory support inadequate
- ICU-acquired weakness/Critical illness myopathy — high risk with prolonged use (>48–72 hours)
- Cardiovascular complications — tachycardia and hypertension may precipitate myocardial ischaemia in susceptible patients
MONITORING REQUIREMENTS
| Timing | Parameters |
|
Baseline
|
Renal function, hepatic function, electrolytes (K⁺, Ca²⁺, Mg²⁺), cardiovascular status |
|
During use
|
Continuous neuromuscular monitoring (TOF/peripheral nerve stimulator); heart rate; BP; SpO₂; ETCO₂; ECG |
|
Before extubation
|
Ensure TOF ratio ≥0.9; clinical assessment (sustained head lift ≥5 seconds, adequate grip strength, vital capacity) |
|
Long-term ICU use
|
Daily assessment of need; drug holidays to assess recovery; monitor for signs of ICU-acquired weakness |
BRANDS AVAILABLE IN INDIA
- Pavulon (Organon)
- Pancuronate (Neon)
- Nupac (Samarth)
- Pancuronium Bromide Injection IP (generic formulations)
Note: No fixed-dose combinations available
PRICE RANGE (INR)
| Formulation | Approximate Price |
| Pancuronium 4 mg (2 mL) ampoule | ₹20–₹40 |
| Pancuronium 10 mg (5 mL) ampoule | ₹40–₹80 |
- Not under NPPA/NLEM price control
- Lower pricing available through government supply channels
- Significantly cheaper than cisatracurium
CLINICAL PEARLS
- Long duration of action — not suitable for short procedures; plan for prolonged recovery or use alternative agents (atracurium, vecuronium) for shorter cases
- Vagolytic effect (tachycardia) — useful when bradycardia is a concern (e.g., with high-dose opioids); avoid in patients where tachycardia is undesirable (coronary artery disease, aortic stenosis)
- Renal excretion limits its use — avoid or reduce dose significantly in renal impairment; prefer atracurium or cisatracurium which undergo organ-independent Hofmann elimination
- Not preferred for ICU paralysis — high accumulation potential and prolonged recovery; increased risk of ICU-acquired weakness; use shortest duration possible
- Always use neuromuscular monitoring — clinical assessment alone is inadequate; TOF monitoring essential due to long and variable duration
- Reversal timing — due to long duration, reversal with neostigmine + glycopyrrolate should be attempted only when spontaneous recovery is evident (TOF ≥2 twitches)
TAGS
pancuronium; neuromuscular blocking agent; NMBA; aminosteroid; anaesthesia; intubation; muscle relaxant; long-acting; vagolytic; renal-excreted; ICU paralysis; Schedule H
VERSION
RxIndia v1.0 — 03 Feb 2026
REFERENCES
- CDSCO-approved prescribing information
- Indian Pharmacopoeia
- National Formulary of India
- AIIMS Anaesthesia protocols
- Goodman & Gilman’s Pharmacological Basis of Therapeutics
- Harrison’s Principles of Internal Medicine
- Indian Society of Critical Care Medicine (ISCCM) — ICU Sedation and Paralysis Guidelines
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.